title: [Limbal stem cell deficiency following multiple intravitreal injections].
abstract: METHODS
  A 68 year-old male with idiopathic choroidal polypoidal vasculopathy received seven intravitreal injections of bevacizumab in the supero-nasal quadrant. He later developed a localized limbal stem cell deficiency which required limbal transplantation from the same eye. Two months after surgery, a slight improvement of visual acuity was noted, along with an intact ocular surface, clear cornea and decreased inflammation.
  
  
  CONCLUSIONS
  Repeated surgical trauma on the limbus and surrounding areas may damage the limbal stem cells, giving rise to a corneal epitheliopathy due to iatrogenic limbal deficiency. Repeated intravitreal injections may be considered as one of the possible causes.
authors.affiliation: Centro de Oftalmología Barraquer, Barcelona, España. mjcapella@barraquer.com
authors.forename: M J
authors.initials: MJ
authors.lastname: Capella
authors.forename: J
authors.initials: J
authors.lastname: Alvarez de Toledo
authors.forename: M F
authors.initials: MF
authors.lastname: de la Paz
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D003131:Combined Modality Therapy; D003316:Corneal Diseases / Q000209:etiology* / Q000473:pathology / Q000601:surgery; D016039:Corneal Transplantation; D019573:Epithelium, Corneal / Q000000981:diagnostic imaging / Q000473:pathology*; D006801:Humans; D058449:Intravitreal Injections / Q000009:adverse effects*; D016850:Limbus Corneae / Q000293:injuries* / Q000473:pathology; D008297:Male; D033401:Microscopy, Acoustic; D010789:Phototherapy; D013234:Stem Cells / Q000473:pathology*; D014182:Transplantation, Autologous
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab